Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections
Center for Infectious Disease and Vaccine Research; Department of Medicine, Division of Infectious Diseases and Immunology
Immunity | Immunology and Infectious Disease | Immunology of Infectious Disease | Infectious Disease
Dengue hemorrhagic fever (DHF), the most severe form of illness following infection with a dengue virus, is characterized by plasma leakage, thrombocytopenia, and hepatic inflammation. The interrelationships among virus burden, immune activation, and development of DHF were examined in 54 children with secondary dengue-3 virus infections participating in a prospective, hospital-based study. DHF was associated with higher mean plasma viremia early in illness and earlier peak plasma interferon-gamma levels. Maximum plasma viremia levels correlated with the degree of plasma leakage and thrombocytopenia. Maximum plasma levels of interleukin (IL)-10 and soluble tumor necrosis factor receptor-II correlated with the degree of thrombocytopenia, independently of viremia levels. Hepatic transaminase elevation correlated with plasma soluble IL-2 receptor levels and not with viremia levels. Quantitative differences in virus burden and host immune responses, and the timing of type 1 cytokine responses, have differing influences on the severity of disease manifestations during secondary dengue-3 virus infections.
Rights and Permissions
Citation: J Infect Dis. 2002 May 1;185(9):1213-21. Epub 2002 Apr 16. doi:10.1086/340365 Link to article on publisher's site
The Journal of infectious diseases
Libraty, Daniel H.; Endy, Timothy P.; Houng, Huo-Shu H.; Green, Sharone; Kalayanarooj, Siripen; Suntayakorn, Saroj; Chansiriwongs, Wanya; Vaughn, David W.; Nisalak, Ananda; Ennis, Francis A.; and Rothman, Alan L., "Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections" (2002). Infectious Diseases and Immunology Publications and Presentations. 281.